IGF::OT::IGF - DEVELOPMENT OF NAMPT INHIBITORS TO TREAT PULMONARY ARTERIAL HYPERTENSION

IGF::OT::IGF - 开发 NAMPT 抑制剂来治疗肺动脉高压

• 批准号: 9523040
• 负责人: ROBERTO MACHADO
• 金额: $ 31.84万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-11-15 至 2019-11-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9523040
• 关键词: Adverse effects; Aortic Aneurysm; Area; Clinical; Coronary Arteriosclerosis; Development; Disease; Dissection; Lymphatic Diseases; Lymphatic System; Peripheral arterial disease; Pharmaceutical Preparations; Pulmonary Hypertension; Research; Thrombosis; Vascular Diseases; Venous; clinical effect; design; inhibitor/antagonist; interest; intracranial artery; nicotinamide phosphoribosyltransferase; product development; programs; pulmonary arterial hypertension; pulmonary vascular disorder; targeted agent

The VITA Program will provide support for early-stage translational development of product candidates in the fields of vascular disorders, thrombotic diseases, and pulmonary hypertension. Proposed project areas of interest may include peripheral arterial disease, aortic aneurysms and dissections, pulmonary vascular disorders, venous and arterial thrombosis, thromboembolic disorders, and disorders of the lymphatic system. Not included as specific topics in this program are diseases of the coronary and intracranial arteries.

VITA计划将为血管疾病，血小板疾病和肺动脉高压领域中产品候选者的早期翻译发展提供支持。提出的感兴趣的项目领域可能包括外周动脉疾病，主动脉瘤和解剖，肺血管疾病，静脉和动脉血栓形成，血栓栓塞性疾病以及淋巴系统的疾病。该计划中的特定主题不包括冠状动脉和颅内动脉的疾病。